120 related articles for article (PubMed ID: 36527836)
21. Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines.
Musso R; Di Cara G; Albanese NN; Marabeti MR; Cancemi P; Martini D; Orsini E; Giordano C; Pucci-Minafra I
J Proteomics; 2013 Sep; 90():115-25. PubMed ID: 23385357
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.
Wada N; Yoshida A; Miyagi Y; Yamamoto T; Nakayama H; Suganuma N; Matsuzu K; Masudo K; Hirakawa S; Rino Y; Masuda M; Imada T
Anticancer Res; 2008; 28(1A):139-44. PubMed ID: 18383837
[TBL] [Abstract][Full Text] [Related]
24. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
25. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
26. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases.
Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS
Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer.
Chiappetta G; De Marco C; Quintiero A; Califano D; Gherardi S; Malanga D; Scrima M; Montero-Conde C; Cito L; Monaco M; Motti ML; Pasquinelli R; Agosti V; Robledo M; Fusco A; Viglietto G
Endocr Relat Cancer; 2007 Jun; 14(2):405-20. PubMed ID: 17639054
[TBL] [Abstract][Full Text] [Related]
28. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment.
Pan Z; Xu T; Bao L; Hu X; Jin T; Chen J; Chen J; Qian Y; Lu X; Li L; Zheng G; Zhang Y; Zou X; Song F; Zheng C; Jiang L; Wang J; Tan Z; Huang P; Ge M
Mol Cancer; 2022 Oct; 21(1):190. PubMed ID: 36192735
[TBL] [Abstract][Full Text] [Related]
29. Not the same thing: metastatic PTCs have a different background than ATCs.
de Biase D; Torricelli F; Ragazzi M; Donati B; Kuhn E; Visani M; Acquaviva G; Pession A; Tallini G; Piana S; Ciarrocchi A
Endocr Connect; 2018 Dec; 7(12):1370-1379. PubMed ID: 30400028
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of autophagy mitigates cell migration and invasion in thyroid cancer.
Holm TM; Bian ZC; Manupati K; Guan JL
Surgery; 2022 Jan; 171(1):235-244. PubMed ID: 34565609
[TBL] [Abstract][Full Text] [Related]
31. Synchronous and antecedent nonthyroidal malignancies in patients with papillary thyroid carcinoma.
Murray SE; Schneider DF; Bauer PS; Sippel RS; Chen H
J Am Coll Surg; 2013 Jun; 216(6):1174-80. PubMed ID: 23522438
[TBL] [Abstract][Full Text] [Related]
32. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
33. Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines.
Takano T; Ito Y; Matsuzuka F; Miya A; Kobayashi K; Yoshida H; Miyauchi A
Oncol Rep; 2007 Sep; 18(3):715-20. PubMed ID: 17671725
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
35. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
36. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor subtype expression in human thyroid tumours.
Klagge A; Krause K; Schierle K; Steinert F; Dralle H; Fuhrer D
Horm Metab Res; 2010 Apr; 42(4):237-40. PubMed ID: 20094970
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor.
Witte J; Lehmann S; Wulfert M; Yang Q; Röher HD
World J Surg; 2007 Jan; 31(1):51-9. PubMed ID: 17171498
[TBL] [Abstract][Full Text] [Related]
39. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
[TBL] [Abstract][Full Text] [Related]
40. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
